Achillion Pharmaceuticals

Achillion Pharmaceuticals is an innovative biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. The company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. The company’s focus is currently on developing three clinical candidates for the treatment of chronic hepatitis C infection. First, Achillion is developing ACH-1625, a proprietary NS3 protease inhibitor currently in early-stage clinical development. Second, Achillion is developing ACH-1095, a candidate from a unique class of compounds called NS4A antagonists that have been demonstrated to be synergistic or additive with other inhibitors under development for HCV infection. Finally, Achillion is developing ACH-2684, a highly potent, pan-genotypic inhibitor of HCV NS3 protease with pico-molar potency. Achillion is also developing ACH-702, its candidate for the treatment of serious, resistant bacterial infections. Each of these programs was discovered through Achillion’s own proprietary internal drug discovery efforts.